TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)

Brittany Bunch, Nithya Krishnan, Rebecca D. Greenspan, Swathi Ramakrishnan, Kristopher Attwood, Li Yan, Qianya Qi, Dan Wang, Carl Morrison, Angela Omilian, Wiam Bshara, Roberto Pili, Donald L. Trump, Candace Johnson, Anna Woloszynska

Research output: Contribution to journalArticle

Abstract

Intrinsic and/or acquired resistance to cisplatin is a significant obstacle in the treatment of muscle-invasive bladder cancer. p73, a p53 homolog and determinant of chemosensitivity, is rarely mutated in bladder cancer (BC). However p73 expression and therefore function can be repressed through epigenetic changes. In this study, we sought to identify DNA methylation status of p73, expression of TAp73 isoform, and their role in cisplatin sensitivity in BC. Primary tumor samples from 338 bladder cancer patients showed decreased TAp73 expression in MIBC compared to superficial BC. Low TAp73 protein expression was associated with shorter overall survival. To investigate if the loss of expression was methylation dependent, we utilized Illumina 450K methylation arrays to interrogate over 150 BC patient samples. We found 12 distinct CpGs in the p73 gene locus that were hypermethylated in tumors compared to adjacent normal tissues. Patients with high p73 promoter methylation specifically at CpG site cg07382920 had worse survival. In vitro, treatment with a DNA demethylating agent, decitabine (DAC), decreased TAp73 methylation and upregulated expression in both CR-T24 (cisplatin resistant T24 cells) and wild type T24 cells. Furthermore, treatment with DAC increased cisplatin response in wild type T24 and CR-T24. Our studies indicate that TAp73 expression and P1 promoter methylation, specifically at the cg073892920 site, may have prognostic and diagnostic value in MIBC. In the setting of P1 promoter hypermethylation, DAC could be used as a potentiating agent of cisplatin-based chemotherapy.

Original languageEnglish (US)
Pages (from-to)2055-2066
Number of pages12
JournalCell Cycle
Volume18
Issue number17
DOIs
StatePublished - Sep 2 2019

Fingerprint

Urinary Bladder Neoplasms
Methylation
Cisplatin
decitabine
Muscles
Survival
Therapeutics
DNA Methylation
Epigenomics
Neoplasms
Protein Isoforms
Drug Therapy
DNA
Genes
Proteins

Keywords

  • bladder cancer
  • epigenetics
  • methylation
  • P73

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology

Cite this

TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC). / Bunch, Brittany; Krishnan, Nithya; Greenspan, Rebecca D.; Ramakrishnan, Swathi; Attwood, Kristopher; Yan, Li; Qi, Qianya; Wang, Dan; Morrison, Carl; Omilian, Angela; Bshara, Wiam; Pili, Roberto; Trump, Donald L.; Johnson, Candace; Woloszynska, Anna.

In: Cell Cycle, Vol. 18, No. 17, 02.09.2019, p. 2055-2066.

Research output: Contribution to journalArticle

Bunch, B, Krishnan, N, Greenspan, RD, Ramakrishnan, S, Attwood, K, Yan, L, Qi, Q, Wang, D, Morrison, C, Omilian, A, Bshara, W, Pili, R, Trump, DL, Johnson, C & Woloszynska, A 2019, 'TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)', Cell Cycle, vol. 18, no. 17, pp. 2055-2066. https://doi.org/10.1080/15384101.2019.1638693
Bunch, Brittany ; Krishnan, Nithya ; Greenspan, Rebecca D. ; Ramakrishnan, Swathi ; Attwood, Kristopher ; Yan, Li ; Qi, Qianya ; Wang, Dan ; Morrison, Carl ; Omilian, Angela ; Bshara, Wiam ; Pili, Roberto ; Trump, Donald L. ; Johnson, Candace ; Woloszynska, Anna. / TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC). In: Cell Cycle. 2019 ; Vol. 18, No. 17. pp. 2055-2066.
@article{f15380ca4d0446db9cabfed4dc68d73c,
title = "TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)",
abstract = "Intrinsic and/or acquired resistance to cisplatin is a significant obstacle in the treatment of muscle-invasive bladder cancer. p73, a p53 homolog and determinant of chemosensitivity, is rarely mutated in bladder cancer (BC). However p73 expression and therefore function can be repressed through epigenetic changes. In this study, we sought to identify DNA methylation status of p73, expression of TAp73 isoform, and their role in cisplatin sensitivity in BC. Primary tumor samples from 338 bladder cancer patients showed decreased TAp73 expression in MIBC compared to superficial BC. Low TAp73 protein expression was associated with shorter overall survival. To investigate if the loss of expression was methylation dependent, we utilized Illumina 450K methylation arrays to interrogate over 150 BC patient samples. We found 12 distinct CpGs in the p73 gene locus that were hypermethylated in tumors compared to adjacent normal tissues. Patients with high p73 promoter methylation specifically at CpG site cg07382920 had worse survival. In vitro, treatment with a DNA demethylating agent, decitabine (DAC), decreased TAp73 methylation and upregulated expression in both CR-T24 (cisplatin resistant T24 cells) and wild type T24 cells. Furthermore, treatment with DAC increased cisplatin response in wild type T24 and CR-T24. Our studies indicate that TAp73 expression and P1 promoter methylation, specifically at the cg073892920 site, may have prognostic and diagnostic value in MIBC. In the setting of P1 promoter hypermethylation, DAC could be used as a potentiating agent of cisplatin-based chemotherapy.",
keywords = "bladder cancer, epigenetics, methylation, P73",
author = "Brittany Bunch and Nithya Krishnan and Greenspan, {Rebecca D.} and Swathi Ramakrishnan and Kristopher Attwood and Li Yan and Qianya Qi and Dan Wang and Carl Morrison and Angela Omilian and Wiam Bshara and Roberto Pili and Trump, {Donald L.} and Candace Johnson and Anna Woloszynska",
year = "2019",
month = "9",
day = "2",
doi = "10.1080/15384101.2019.1638693",
language = "English (US)",
volume = "18",
pages = "2055--2066",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "17",

}

TY - JOUR

T1 - TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)

AU - Bunch, Brittany

AU - Krishnan, Nithya

AU - Greenspan, Rebecca D.

AU - Ramakrishnan, Swathi

AU - Attwood, Kristopher

AU - Yan, Li

AU - Qi, Qianya

AU - Wang, Dan

AU - Morrison, Carl

AU - Omilian, Angela

AU - Bshara, Wiam

AU - Pili, Roberto

AU - Trump, Donald L.

AU - Johnson, Candace

AU - Woloszynska, Anna

PY - 2019/9/2

Y1 - 2019/9/2

N2 - Intrinsic and/or acquired resistance to cisplatin is a significant obstacle in the treatment of muscle-invasive bladder cancer. p73, a p53 homolog and determinant of chemosensitivity, is rarely mutated in bladder cancer (BC). However p73 expression and therefore function can be repressed through epigenetic changes. In this study, we sought to identify DNA methylation status of p73, expression of TAp73 isoform, and their role in cisplatin sensitivity in BC. Primary tumor samples from 338 bladder cancer patients showed decreased TAp73 expression in MIBC compared to superficial BC. Low TAp73 protein expression was associated with shorter overall survival. To investigate if the loss of expression was methylation dependent, we utilized Illumina 450K methylation arrays to interrogate over 150 BC patient samples. We found 12 distinct CpGs in the p73 gene locus that were hypermethylated in tumors compared to adjacent normal tissues. Patients with high p73 promoter methylation specifically at CpG site cg07382920 had worse survival. In vitro, treatment with a DNA demethylating agent, decitabine (DAC), decreased TAp73 methylation and upregulated expression in both CR-T24 (cisplatin resistant T24 cells) and wild type T24 cells. Furthermore, treatment with DAC increased cisplatin response in wild type T24 and CR-T24. Our studies indicate that TAp73 expression and P1 promoter methylation, specifically at the cg073892920 site, may have prognostic and diagnostic value in MIBC. In the setting of P1 promoter hypermethylation, DAC could be used as a potentiating agent of cisplatin-based chemotherapy.

AB - Intrinsic and/or acquired resistance to cisplatin is a significant obstacle in the treatment of muscle-invasive bladder cancer. p73, a p53 homolog and determinant of chemosensitivity, is rarely mutated in bladder cancer (BC). However p73 expression and therefore function can be repressed through epigenetic changes. In this study, we sought to identify DNA methylation status of p73, expression of TAp73 isoform, and their role in cisplatin sensitivity in BC. Primary tumor samples from 338 bladder cancer patients showed decreased TAp73 expression in MIBC compared to superficial BC. Low TAp73 protein expression was associated with shorter overall survival. To investigate if the loss of expression was methylation dependent, we utilized Illumina 450K methylation arrays to interrogate over 150 BC patient samples. We found 12 distinct CpGs in the p73 gene locus that were hypermethylated in tumors compared to adjacent normal tissues. Patients with high p73 promoter methylation specifically at CpG site cg07382920 had worse survival. In vitro, treatment with a DNA demethylating agent, decitabine (DAC), decreased TAp73 methylation and upregulated expression in both CR-T24 (cisplatin resistant T24 cells) and wild type T24 cells. Furthermore, treatment with DAC increased cisplatin response in wild type T24 and CR-T24. Our studies indicate that TAp73 expression and P1 promoter methylation, specifically at the cg073892920 site, may have prognostic and diagnostic value in MIBC. In the setting of P1 promoter hypermethylation, DAC could be used as a potentiating agent of cisplatin-based chemotherapy.

KW - bladder cancer

KW - epigenetics

KW - methylation

KW - P73

UR - http://www.scopus.com/inward/record.url?scp=85070078517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070078517&partnerID=8YFLogxK

U2 - 10.1080/15384101.2019.1638693

DO - 10.1080/15384101.2019.1638693

M3 - Article

C2 - 31318640

AN - SCOPUS:85070078517

VL - 18

SP - 2055

EP - 2066

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 17

ER -